orserdu.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Allow: / Host: https://www.orserdu.com/ Sitemap: | ||
Meta Tags
| Title | ER+/HER2- ESR1m mBC Treatment | ORSERDU™ |
| Description | First and only treatment approved for ER+/HER2- ESR1-mutated Discover ORSERDU™, the first and only approved treatment for people with ER+/HER2- ESR1-mutated metastatic breast cancer following initial hormone |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 3.208.146.84 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
orserdu.com Valuation
|
US$1,737
Last updated: 2023-05-20 08:56:56
orserdu.com has Semrush global rank of 0. orserdu.com has an estimated worth of US$ 1,737, based on its estimated Ads revenue. orserdu.com receives approximately 200 unique visitors each day. Its web server is located in United States, with IP address 3.208.146.84. According to SiteAdvisor, orserdu.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$1,737 |
| Daily Ads Revenue | US$1 |
| Monthly Ads Revenue | US$48 |
| Yearly Ads Revenue | US$577 |
| Daily Unique Visitors | 13 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| orserdu.com. | A | 299 | IP: 3.208.146.84 |
| orserdu.com. | NS | 300 | NS Record: ns.abdns.eu. |
| orserdu.com. | NS | 300 | NS Record: ns.abdns.biz. |
| orserdu.com. | NS | 300 | NS Record: ns.abdns.info. |
| orserdu.com. | MX | 300 | MX Record: 10 in.arubabusiness.it. |
| orserdu.com. | TXT | 300 | TXT Record: v=spf1 a mx include:_spf.arubabusiness.it -all |
HtmlToTextCheckTime:2023-05-20 08:56:56
| ONCE-DAILY TABLET Important Safety Information Important Safety Information Patient Information Full Prescribing Information Healthcare Professional Site Home Understanding ESR1 mutations ORSERDU results Taking ORSERDU ORSERDU safety Helpful resources Savings and support First and only treatment approved for ER+/HER2- ESR1 -mutated mBC Home Understanding ESR1 mutations ORSERDU results Taking ORSERDU ORSERDU safety Helpful resources Savings and support Patient Information Full Prescribing Information Healthcare Professional Site For postmenopausal women and adult men with ER+/HER2- ESR1 -mutated mBC following initial hormone therapy First and only treatment approved for ER+/HER2- ESR1 -mutated mBC Not actual patients. You have been prescribed ORSERDU See clinical trial results Find out more about if ORSERDU is right for you Learn about ESR1 mutations and testing ER+, estrogen receptor-positive; ESR1 , estrogen receptor 1; HER2-, human epidermal growth factor receptor 2-negative; mBC, |
HTTP Headers
HTTP/1.1 301 Moved Permanently Content-Length: 143 Content-Type: text/html; charset=UTF-8 Location: https://orserdu.com/ Server: Microsoft-IIS/10.0 Date: Sun, 29 Jan 2023 08:56:33 GMT HTTP/2 301 content-length: 147 content-type: text/html; charset=UTF-8 location: https://www.orserdu.com/ server: Microsoft-IIS/10.0 date: Sun, 29 Jan 2023 08:56:33 GMT HTTP/2 200 content-length: 8661 content-type: text/html last-modified: Fri, 27 Jan 2023 23:05:56 GMT accept-ranges: bytes etag: "02257e9a332d91:0" server: Microsoft-IIS/10.0 date: Sun, 29 Jan 2023 08:56:33 GMT |